I doubt you are a shareholder too. A real shareholders would never be hostile to legitimate questions like I ask. I don’t think the 10Q provided a credible explanation for why we have no meaningful Specials revenue or it would have been trumpeted by management supporters repeatedly.
And it shows only $405K revenue for last Q. A number that is very disconnected from what most assume the revenue should be.
Some have tried to argue a time lag as the disconnect. That does not work as we would be seeing increasing sequential. It is not.
Some are arguing that there are costs. But costs do not reduce top line revenue. They are subtracted farther down on the P&L from that number.. And we do see costs for Specials reported as $11.5M for last year. (Note, for dev stage drugs, mfg costs go under R&D, not COGS)
Some are arguing they are running a stealth trial for Eden or poly-ICLC or whatever. But we see no indication of this.
Some argue that Advent gets the revenue and pays NWBO some percent. That does make numbers work, but would be very fraudulent reporting to not disclose it.
Or maybe they basically just have nearly no sales despite the hype. And if so, why?
News 
Market Data 
Discover 
